Novavax, Inc. (NVAX)
Nasdaq · Healthcare · Biotechnology
$12.56+20.08%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $2.1B
- 52-week range
- $6.20 – $13.39
- 52-week change
- +13.45%
- EPS (trailing)
- −$1.58
- Analyst rating
- 2.3 Buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $1.1B (+64.70%)
- Net income
- $440M
- Operating margin
- 40.3%
- Diluted EPS
- $2.58
From the company’s annual report on SEC EDGAR.
About Novavax, Inc.
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Headquarters: Gaithersburg, United States · 749 employees · novavax.com